亚甲基四氢叶酸还原酶基因多态性与乳腺癌化疗敏感性的关系

唐金海; 陆建伟; 高长明; 吴建中; 秦建伟; 俞乔; 曹海霞; 尹必俭; 周兆飞

doi:10.3969/j.issn.1672-2353.2006.09.011

亚甲基四氢叶酸还原酶基因多态性与乳腺癌化疗敏感性的关系

1.
江苏省肿瘤防治研究所,普外科,江苏,南京,210009;
2.
江苏省肿瘤防治研究所,内科,江苏,南京,210009;
3.
江苏省肿瘤防治研究所流行病研究室,江苏,南京,210009

基金项目: 江苏省科学技术厅社会发展重大项目

详细信息

中图分类号: R737.9
计量
- 文章访问数: 140
- HTML全文浏览量: 25
- PDF下载量: 10
出版历程
- 发布日期: 2006-12-04

METHYLENE TETRAHYDROFOLATE REDUCTASE POLYMORPHISM ON CHEMOSENSITIVITY OF ADVANCED BREAST CANCER

摘要

摘要: 目的观察叶酸代谢的关键酶亚甲基四氢叶酸还原酶(MTHFR)基因C677T、A1298C多态与乳腺癌患者对化疗敏感性的关系.方法收集经病理学确诊的晚期乳腺癌患者61例,所有病例化疗前抽静脉血,提取白细胞DNA,用PCR-RFLP技术检测MTHFR基因型.接受6种不同的化疗方案化疗.结果 61例乳腺癌癌患者中,MTHFR C/C基因型17例(27.9%)、C/T 29例(47.5%)、T/T 15例(24.6%).MTHFR A1298C A/A基因型42例(68.9%),17例(27.9%)A/C基因型,2例(3.3%)C/C基因型.化疗总有效率为67.2%(41/61),其中CR3例(4.9%),PR38例(62.3%),SD15例(24.6%),PD5例(8.2%).6种化疗方案的有效率无统计学差异(P＝0.397).MTHFR C/C基因型、C/T基因型、T/T基因型的有效率分别为58.8%、58.6%、93.3%,T/T基因型患者的有效率显著高于C/C基因型(P＝0.041)和C/T基因型患者(P＝0.034).MTHFR A1298C A/A基因型、A/C基因型、C/C基因型的有效率分别为71.4%、64.7%、0.0%,MTHFR A1298C A/A基因型患者的有效率与A/C基因型(P＝0.756)、C/C基因型患者之间无统计学差异(P＝0.096).结论本研究初步结果显示MTHFR C677T基因多态性对预测乳腺癌化疗疗效具有较好的临床应用价值.
- 乳腺癌晚期 /
- 亚甲基四氢叶酸还原酶 /
- 化学治疗 /
- 基因型

HTML全文

参考文献(20)

Frosst P, Blom H J, Milos P. A candidate genetic risk factor for vascular disease:a common mutation in methylenetetrahydrofolate reductase [J]. Nature Genetics, 1995.111.doi: 10.1038/ng0595-111.

Weisberg I, Tran P, Christensen B. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity [J]. Molecular Genetics and Metabolism, 1998.169.

Botto L D, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies:a HuGE review [J]. American Journal of Epidemiology, 2000.862.

Song C, Xing D, Tan W. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population [J]. CANCER RESEARCH, 2001.3272.

Robien K, Ulrich C M. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk:a HuGE minireview [J]. American Journal of Epidemiology, 2003.571.doi: 10.1093/aje/kwg024.

Satoh A, Toyota M, Itoh F. Epigenetic Inactivation of CHFR and Sensitivity to Microtubule Inhibitors in Gastric Cancer [J]. CANCER RESEARCH, 2003, (24):8606.

Narayan G, Arias-Pulido H, Nandula S V. Promoter Hypermethylation of FANCF-Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer [J]. Cancer Research, 2004(9):2994.doi: 10.1158/0008-5472.CAN-04-0245.

Chekhun V F, Kulik G I, Yurchenko O V. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells [J]. Cancer Letters, 2006(1):87.doi: 10.1016/j.canlet.2005.01.038.

Suzuki H, Itoh F, Toyota M. Inactivation of the 14-3-3δ sigma gene is associated with 5' CpG island hypermethylation in human cancers [J]. Cancer Research, 2000, (16):4353.

Chiusolo P, Reddiconto G, Casorelli I. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate [J]. Annals of Oncology, 2002, (12):1915.doi: 10.1093/annonc/mdf322.

Toffoli G, Veronesi A, Boiocchi M. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) [J]. Annals of Oncology, 2000, (3):373.doi: 10.1023/A:1008337900349.

Toffoli G, Russo A, Innocenti F. Effect of methylenetetrahydrofolate reductase 677C＞T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients [J]. International Journal of Cancer, 2003.294.doi: 10.1002/ijc.10847.

Cohen V, Panet-Raymond V, Sabbaghian N. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer:a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy [J]. Clinical Cancer Research, 2003.1611.

Ruzzo A, Graziano F, Kawakami K. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy [J]. Journal of Clinical Oncology, 2006, (12):1883.doi: 10.1200/JCO.2005.04.8322.

Lu J W, Gao C M, Wu J Z. Relationship of Methylenetetrahydrofolate Reductase C677T Polymorphism and Chemosensitivity to 5-Fluorouracil in Gastric Carcinoma [J]. Chinese Journal of Cancer, 2004(8):958.doi: 10.3321/j.issn:1000-467X.2004.08.021.

Stern L L, Mason J B, Selhub J. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene [J]. Cancer Epidemiology Biomarkers and Prevention, 2000(8):849.

Shrubsole M J, Shu X O, Ruan Z X. MTHFR genotypes and breast cancer survival after surgery and chemotherapy:a report from the Shanghai Breast Cancer Study [J]. Breast Cancer Research and Treatment, 2005(1):73.doi: 10.1007/s10549-004-7265-6.

唐金海, 赵建华. 生物芯片技术的发展及其在乳腺癌研究中应用 [J]. 实用临床医药杂志, 2006(2):26.doi: 10.3969/j.issn.1672-2353.2006.03.007.

沈坤炜. 2005 St.Gallen 国际乳腺癌治疗共识 [J]. 实用临床医药杂志, 2006(2):26-28.doi: 10.3969/j.issn.1672-2353.2006.03.008.

武正炎. NCCN乳腺癌临床实践指南(2006版)简介 [J]. 实用临床医药杂志,.

施引文献

资源附件(0)

计量

文章访问数: 140
HTML全文浏览量: 25
PDF下载量: 10
被引次数: 0

亚甲基四氢叶酸还原酶基因多态性与乳腺癌化疗敏感性的关系

计量

出版历程

METHYLENE TETRAHYDROFOLATE REDUCTASE POLYMORPHISM ON CHEMOSENSITIVITY OF ADVANCED BREAST CANCER

计量

出版历程

目录